Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster)

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Martin, Amanda C ^a   Johnston, Ed ^b   Xing, Chengguo ^a,c   Hegeman, Adrian D ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Alia Point 'Awa Nursery   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; FLAVOKAWAIN A; FLAVOKAWAIN B; KAVA EXTRACT; KAWAIN; METHYSTICIN; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; WATER; KAVA; PLANT EXTRACT;

A549 CELL LINE; ARTICLE; CELL VIABILITY; CHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN CELL; METABOLOMICS; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FRACTIONATION; IC50; MEDICINAL PLANT; PROCEDURES; TUMOR CELL LINE;

PIPER METHYSTICUM;

CELL LINE, TUMOR; CELL SURVIVAL; CHEMICAL FRACTIONATION; HUMANS; INHIBITORY CONCENTRATION 50; KAVA; METABOLOMICS; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 84909619250     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111572     Document Type: Article

References (48)

1. E Johnston, H Rogers (2006) Introduction, Hawaiian Cultivars, and Non-Hawaiian Cultivars Grown in Hawai'i Today. In: E Johnston, H Rogers, editors. Hawaiian 'Awa: Views of an ethnobotanical treasure. Hilo, Hawaii: Association for Hawaiian 'Awa, pp. 1-7, 30-63.
2. He X, Lin L, Lian L (1997) Electrospray high performance liquid chromatography-mass-spectrometry in phytochemical analysis of kava (Piper methysticum) extract. Planta Med 63: 70-74.
3. Sarris J, Teschke R, Stough C, Scholey A, Schweltzer I (2011) Re-introduction of kava (Piper methysticum) to the EU: Is there a way forward? Planta Med 77: 107-110.
4. Steiner G (2000) The correlation between cancer incidence and kava consumption. Hawaii Med J 59: 420-422.
5. Johnson TE, Kassie F, O'Sullivan MG, Negia M, Hanson TE, et al. (2008) Johnson, Chemopreventive effect of kava on 4-(Methylnitrosamino)-1-(3-pryridyl)-1-butanone plus Benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Can Prev Res 1: 430-438.
6. Johnson TE, Hermanson D, Wang L, Kassie F, Upadhyaya P, et al. (2011) Lung tumorigenesis suppressing effects of commercial kava extract and its selected compounds in A/J mice. Am J Chinese Med 39: 727-742.
7. Leitzman P, Narayanapillai SC, Balbo S, Zhou B, Upadhyaya P, et al. (2014) Kava blocks 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-Induced lung tumorigenesis in association with reducing O6-methylguanine DNA adduct in A/J Mice. Cancer Prev Res 7: 86-96.
8. Zi X, Simoneau AR (2005) Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of bax proteindependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res, 65: 3479-3486.
9. Teschke R, Sarris J, Glass X, Schulze J (2011) Kava, the anxiolytic herb: back to basics to prevent liver injury? British Journal of Clinical Pharmacology 71: 445-448.
10. Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, et al. (2001) Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Medica 67: 306-311.
11. Jokhan AD and McLenachan PA (2004) Genetic fingerprinting of Fijian kava. S Pac J Nat Sci 22: 43-45.
12. Lebot V, Siméoni P (2004) Is the quality of kava (Piper methysticum Forst f.) responsible for different geographical patterns. Ethnobotany Res App 2: 19-28.
13. Lebot V, Johnston E, Zheng QZ, McKern D, McKenna DJ (1999) Morphological, phytochemical, and genetic variation in Hawaiian cultivars of 'awa (Kava, Piper methysticum, Piperaceae). Econ Bot 53: 407-418.
14. Dasgupta A, Hammett-Stabler CA (2011) Abnormal Liver Function Tests Due to Hepatotoxic Herbs. In: Dasgupta A, Hammett-Stabler C A, editors. Herbal supplements: Efficacy, toxicity, interactions with western drugs, and effects on clinical tests. New York: Wiley, New York. pp. 155-167.
15. Shao Y, He K, Zheng B, Zheng Q (1998) Reversed-phase high-performance liquid chromatographic method for quantitative analysis of the six major kavalactones in Piper methysticum. J Chromatogr A 825: 1-8.
16. Siméoni P, Lebot V (2002) Identification of factors determining kavalactone content and chemotype in kava (Piper methysticum Forst. F.). Biochem Syst Ecol 30: 413-424.
17. Teschke R, Sarris J, Lebot V (2011) Kava hepatotoxicity solution: A six-point plan for new kava standardization. Phytomedicine; 18: 96-103.
18. Lebot V, Do TKT, Legendre L (2014) Detection of Flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem 151: 554-560.
19. Lebot V (2006) The quality of kava consumed in the South Pacific. HerbalGram. 71: 34-37.
20. Teschke R, Genthner A, Wolff A (2009) Kava hepatotoxicity: Comparison of aqueous, ethanolic, acetonic kava extracts and kava-herbs mixtures. J Ethnopharmacol 123: 378-384.
21. Jhoo JW, Freeman JP, Heinze TM, Moody JD, Schnackenberg LK, et al. (2006) In vitro cytotoxicity of nonpolar constituents from different parts of kavaplant (Piper methysticum). J Agr Food Chem 54: 3157-3162.
22. Johansen NH, Glitse V, Knudsen KEB (1996) Influence of extraction solvent and temperature on the quantitative determination of oligosaccharides from plant materials by high-performance liquid chromatography. J Agric Food Chem 44: 1470-1474.
23. Lapornik B, Prosek M, Wondra G A (2005) Comparison of extracts prepared from plant by-products using different solvents and extraction time, J Food Eng 71: 214-222.
24. Shaik AA, Hermanson DL, Xing C (2009) Identification of methysticin as a potent and non-toxic NF-kB inhibitor from kava, potentially responsible for kava's chemopreventive actvity. Bioorg. Med Chem Lett 19: 5732-5736.
25. Zhou P, Gross S, Liu J, Yu B, Feng L, et al, (2010) Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kB and MAPK signaling pathways. FASEB J 24: 4722-4732.
26. Teschke R, Qiu SX, Xuan TD, Lebot V (2011) Kava and kava hepatotoxicity: Requirements for novel experimental, ethnobotanical, and clinical studies based on a review of the evidence. Phytother Res, 25: 1263-1274.
27. Teschke R, Qiu SX, Lebot V (2011) Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Digestive and Liver Disease, 43: 676-681.
28. Teschke R, Lebot V (2011) Proposal for a kava quality standard code. Food and Chem Toxicol. 49: 2503-2516.
29. Teschke R (2011) Kava and the risk of liver toxicity: past, current, and future. Am Herb Prod Assoc Rep 26: 8-17.
30. Teschke R, Gaus W, Loew D (2003) Kava extracts: Safety and risks including rare hepatotoxicity. Phytomedicine 10: 440-446.
31. U.S. Food and Drug Administration (2002) Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury (FDA Publication, www.fda.gov/Food/ResourcesForYou/Consumers/ucm085482.htm, date accessed: January 11, 2014).
32. Zhang LY, Rowe A, Ramzan I (2011) Does inflammation play a role in kava hepatotoxicity. Phytother Res 25: 629-630.
33. Fiji Bureau of Statistics (2013) 2011 Export Statistics. Fiji Bureau of Statistics Publicatio. Available: http://www.statsfiji.gov.fj/index.php/document-library/ cat-view/12-economic-statistics/17-international-trade?start=25. Accessed: March 18, 2014.
34. Tonga Statistics Department (2008-2012) Kingdom of Tonga annual foreign trade report. Nuku'alofa Statistics Department Publication. Available: www.spc. int/prism/tonga/index.php/economic/merchandise-trade/export. Accessed: March 18, 2014.
35. Vanuatu National Statistics Office (2013) Statistics Update: Overseas Trade, August 2013 Highlights. Vanuatu National Statistics Office Publication. Available: http://www.vnso.gov.vu/index.php/economic-statistics/economicsummary. Accessed: March 18, 2014.
36. Discussion paper on the development of a standard for kava products (2012) Codex Alimentarius Commission (FAO/WHO), Food Standards Programme, 12th session, agenda item 6.
37. Johnson BM, Qiu S, Zhang S, Burdette JE, Yu L, et al. (2003) Identification of novel electrophilic metabolites of Piper methysticum Forst. (Kava). Chem Res Toxicol 16: 733-740.
38. Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS (2003) Kava lactones and the kava-kava controversy. Phytochemistry 64: 673-679.
39. Olsen LR, Grillo MP, Skonberg C (2011) Constituents in kava extracts potentially involved in hepatotoxicity: A Review. Chem Res Toxicol 24: 992-2002.
40. Anke J, Ramzan I (2004) Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.). J Ethnopharmacol 93: 153-160.
41. Behl M, Nyska A, Chhabra RS, Travlos GS, Fomby LM, et al. (2011) Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava. Food Chem Toxicol 49: 2820-2829.
42. Zou L, Henderson GL, Harkey MR, Sakai Y, Li A (2004) Effects of kava (Kavakava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 11: 285-294.
43. Yang X, Salminen W F (2011) Kava extract, an herbal alternative for anxiety relief, potentiates acetaminophen-induced cytotoxicity in rat hepatic cells. Phytomedicine 18: 592-600.
44. Smith RM, Thakrar H, Arowolo TA, Shafi AA (1984) High-performance liquid chromatography of kava lactones from Piper methysticum. J Chromatogr 283: 303-308.
45. Meissmer O and Haberlein H (2005) HPLC analysis of flavokavins and kavapyrones from Piper methysticum Forst. Journal of Chromatography B, 826: 46-49.
46. Hegeman AD (2010) Plant metabolomics-meetings the analytical challenges of comprehensive metabolite analysis. Brief Funct Gen 9: 139-148.
47. Dragull K, Yoshida WY, Tang C (2003) Piperidine alkaloids from Piper methysticum. Phytochemistry 63: 193-198.
48. Warmka JK, Solberg EL, Zeliadt NA, Srinivasan B, Charlson AT, et al. (2012) Inhibition of mitogen activated protein kinases increases the sensitivity of A549 lung cancer cells to the cytotoxicity induced by a kava chalcone analog. Biochem Biophys Res Comm 424: 488-492.